Literature DB >> 21217677

Adenosine receptor crossroads in sickle cell disease.

Mark T Gladwin.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21217677     DOI： 10.1038/nm0111-38

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  13 in total

1.  Detrimental effects of adenosine signaling in sickle cell disease.

Authors:  Yujin Zhang; Yingbo Dai; Jiaming Wen; Weiru Zhang; Almut Grenz; Hong Sun; Lijian Tao; Guangxiu Lu; Danny C Alexander; Michael V Milburn; Louvenia Carter-Dawson; Dorothy E Lewis; Wenzheng Zhang; Holger K Eltzschig; Rodney E Kellems; Michael R Blackburn; Harinder S Juneja; Yang Xia
Journal:  Nat Med       Date:  2010-12-19       Impact factor: 53.440

2.  AMISTAD trials: possible reasons for lack of success.

Authors:  Michael V Cohen; James M Downey
Journal:  J Am Coll Cardiol       Date:  2006-02-23       Impact factor: 24.094

3.  Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial.

Authors:  K W Mahaffey; J A Puma; N A Barbagelata; M F DiCarli; M A Leesar; K F Browne; P R Eisenberg; R Bolli; A C Casas; V Molina-Viamonte; C Orlandi; R Blevins; R J Gibbons; R M Califf; C B Granger
Journal:  J Am Coll Cardiol       Date:  1999-11-15       Impact factor: 24.094

4.  The disappearance of adenosine from blood and platelet suspension in relation to the platelet cyclic AMP content.

Authors:  U Söderbäck; A Sollevi; B B Fredholm
Journal:  Acta Physiol Scand       Date:  1987-02

5.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease.

Authors:  Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin
Journal:  Nat Med       Date:  2002-11-11       Impact factor: 53.440

Review 6.  Possible role of adenosine deaminase in vaso-occlusive diseases.

Authors:  E K Jackson; M Koehler; Z Mi; R K Dubey; S P Tofovic; J A Carcillo; G S Jones
Journal:  J Hypertens       Date:  1996-01       Impact factor: 4.844

7.  Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease.

Authors:  Kori L Wallace; Joel Linden
Journal:  Blood       Date:  2010-08-26       Impact factor: 22.113

8.  Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling.

Authors:  Tiejuan Mi; Shahrzad Abbasi; Hong Zhang; Karen Uray; Janci L Chunn; Ling Wei Xia; Jose G Molina; Norman W Weisbrodt; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

9.  PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years.

Authors:  M S Hershfield
Journal:  Clin Immunol Immunopathol       Date:  1995-09

10.  NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.

Authors:  Kori L Wallace; Melissa A Marshall; Susan I Ramos; Joanne A Lannigan; Joshua J Field; Robert M Strieter; Joel Linden
Journal:  Blood       Date:  2009-05-11       Impact factor: 22.113
View more
  9 in total

Review 1.  Metabolomics as a key integrator for "omic" advancement of personalized medicine and future therapies.

Authors:  Andrea D Eckhart; Kirk Beebe; Mike Milburn
Journal:  Clin Transl Sci       Date:  2012-06       Impact factor: 4.689

Review 2.  Ischemia and reperfusion--from mechanism to translation.

Authors:  Holger K Eltzschig; Tobias Eckle
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

3.  Probing biased/partial agonism at the G protein-coupled A(2B) adenosine receptor.

Authors:  Zhan-Guo Gao; Ramachandran Balasubramanian; Evgeny Kiselev; Qiang Wei; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2014-05-20       Impact factor: 5.858

4.  Global expression profiling and pathway analysis in two different population groups in relation to high altitude.

Authors:  Supriya Saini; Praveen Vats; Susovon Bayen; Priya Gaur; Koushik Ray; Krishna Kishore; Meerim Sartmyrzaeva; Almaz Akunov; Abdirashit Maripov; Akpay Sarybaev; Bhuvnesh Kumar; Shashi Bala Singh
Journal:  Funct Integr Genomics       Date:  2018-10-19       Impact factor: 3.410

5.  Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice.

Authors:  Almut Grenz; Jessica D Bauerle; Julee H Dalton; Douglas Ridyard; Alexander Badulak; Eunyoung Tak; Eóin N McNamee; Eric Clambey; Radu Moldovan; German Reyes; Jost Klawitter; Kelly Ambler; Kristann Magee; Uwe Christians; Kelley S Brodsky; Katya Ravid; Doo-Sup Choi; Jiaming Wen; Dmitriy Lukashev; Michael R Blackburn; Hartmut Osswald; Imogen R Coe; Bernd Nürnberg; Volker H Haase; Yang Xia; Michail Sitkovsky; Holger K Eltzschig
Journal:  J Clin Invest       Date:  2012-01-24       Impact factor: 14.808

6.  Adora2b adenosine receptor signaling protects during acute kidney injury via inhibition of neutrophil-dependent TNF-α release.

Authors:  Almut Grenz; Jae-Hwan Kim; Jessica D Bauerle; Eunyoung Tak; Holger K Eltzschig; Eric T Clambey
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

Review 7.  The role of adenosine signaling in sickle cell therapeutics.

Authors:  Joshua J Field; David G Nathan; Joel Linden
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 8.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

Review 9.  Blood cells: an historical account of the roles of purinergic signalling.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2015-08-11       Impact factor: 3.765
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.